India's Hetero launches Avastin biosimilar, following Reliance into the market

Roche HQ
Injectable

Hyderabad-based Hetero Drugs has launched a biosimilar of Roche's ($RHHBY) colorectal cancer therapy Avastin (bevacizumab) in India, apparently overcoming a legal challenge by the Big Pharma linked to language on the packaging label that draws on the originator’s clinical work.

The launch, according to Press Trust of India, will see the product called Cizumab available in a single dose vial strengths of 100 and 400 milligrams. The Drug Controller General of India (DGCI) approved the biosimilar version by Hetero as well as one by Mumbai-based Reliance Life Sciences launched earlier in June--the first biosimilar version in India.

The Reliance version, which will be marketed by Mumbai-based Lupin under the name Bevacirel, comes at a price level just shy of the original drug in India with a price gap of INR1,200 ($17.97) for a 100mg injection. Pricing information was unavailable for the Hetero version.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

At least one other company, Ahmedabad-based Intas Pharmaceutical, has an application for a version of bevacizumab pending before the DCGI.

In May, Roche filed a lawsuit to block approval of a biosimilar of the same drug by Hetero, citing the labeling description of clinical outcomes.

- here's the story from Press Trust of India

Related Articles:
India's Reliance Life Sciences brings first bevacizumab biosim to market
Roche presses on biosimilar labels in India with Avastin challenge

Read more on

Suggested Articles

Pfizer's mature drugs plunged in China. AZ and GSK race their oral anemia drugs to Asia. Biotech leaders worry IP crackdown will hurt collaboration.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin.